• Biomimetic Chromatography Models for Pulmonary Drug Permeabi

  2026-05-19

  This study pioneers a comparative evaluation of biomimetic open tubular capillary electrochromatography (OT-CEC) and immobilised artificial membrane liquid chromatography (IAM-LC), both coupled with mass spectrometry, for modeling lung permeability of pharmaceuticals. The findings reveal nuanced strengths and limitations of each technique, providing valuable guidance for high-throughput permeability screening in respiratory drug development.

• ATM-Targeted TACE Silencing Reduces Obesity-Induced Diabetes

  2026-05-19

  This study demonstrates that targeted gene silencing of TACE in visceral adipose tissue macrophages, using the ATS-9R peptide, effectively attenuates obesity-driven inflammation and improves insulin sensitivity in a mouse model. The findings establish a mechanistically precise, non-viral approach for metabolic disease intervention that outperforms nonspecific delivery methods.

• CD28-ARS2 Axis and PKM Splicing Enable CD8+ T Cell Metabolic

  2026-05-18

  This study uncovers how the CD28-ARS2 signaling axis governs alternative splicing of pyruvate kinase (PKM), enabling metabolic flexibility in CD8+ T cells and supporting antitumor immunity. The findings reveal a previously unknown layer of post-transcriptional metabolic regulation, opening avenues for targeted immunometabolic interventions.

• Fluorescein Tyramide: Reliable Signal Amplification in Cell

  2026-05-18

  This article addresses common challenges in cell viability and molecular detection assays, demonstrating how Fluorescein Tyramide (SKU K1084) delivers reproducible, ultrasensitive signal amplification. Bench-tested protocol guidance and real-world scenario analysis help biomedical researchers, technicians, and postgraduate scientists optimize assay performance using this robust fluorescent labeling dye.

• Ranolazine in Cardiac Ischemia Research: Protocols and Insig

  2026-05-17

  Ranolazine’s dual metabolic and electrophysiological actions empower cardiac ischemia research with reproducible, translational workflows. This article distills advanced protocol enhancements and troubleshooting strategies, with a spotlight on Ranolazine’s unique value for metabolic modulation in both cardiac and hepatic models.

• CH 223191: Precision Aryl Hydrocarbon Receptor Antagonist Us

  2026-05-16

  CH 223191 is a validated aryl hydrocarbon receptor antagonist enabling highly reproducible workflows in environmental toxicology and stem cell research. Its nanomolar potency, robust selectivity, and compatibility with complex biological models make it a premier tool for dissecting AhR-dependent mechanisms, including those revealed in microbiota-tryptophan-AhR axis studies.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-05-15

  Schwartz’s dissertation advances in vitro cancer drug evaluation by clearly distinguishing between cell proliferation arrest and cell death, moving beyond traditional composite viability metrics. This distinction enables more accurate characterization of anticancer compound activity, with direct implications for preclinical research and translational assay optimization.

• Paroxetine Mesylate Targets MET/ERBB3 in Colorectal Cancer M

  2026-05-15

  This study provides evidence that Paroxetine Mesylate, a selective serotonin reuptake inhibitor, exerts significant anticancer effects in colorectal cancer by inhibiting MET and ERBB3 receptor tyrosine kinases. The findings support the potential for drug repositioning of Paroxetine Mesylate and offer mechanistic insights for translational oncology research.

• Catalpol in Translational Neuroprotection and Disease Models

  2026-05-14

  Catalpol, a multi-pathway iridoid glycoside, enables reproducible neuroprotection and anti-inflammatory results in both cellular and animal models. By integrating pathway-specific inhibition with neurotrophic enhancement, Catalpol unlocks advanced experimental designs for neuroinflammation, osteoporosis, and ischemic stroke research.

• FPH1 (BRD-6125): Optimizing Hepatocyte Proliferation Workflo

  2026-05-14

  FPH1 (BRD-6125) empowers researchers to achieve donor-independent, scalable expansion of functional hepatocytes, accelerating drug discovery and iPSC-derived hepatocyte workflows. This guide delivers protocol optimizations, troubleshooting advice, and integration tips, all backed by peer-reviewed evidence and real-world scenarios.

• PKM2 Inhibitor (Compound 3k): Precision Glycolysis Disruptio

  2026-05-13

  PKM2 inhibitor (compound 3k) is a powerful tool for selectively disrupting aerobic glycolysis in cancer and immune cell models. This article details protocol strategies, advanced use-cases in cancer and inflammation, and actionable troubleshooting for maximizing data quality with this pyruvate kinase M2 inhibitor.

• Caspase-3 Colorimetric Assay Kit: Precision in Apoptosis Ana

  2026-05-13

  The Caspase-3 Colorimetric Assay Kit empowers researchers with rapid, quantitative detection of DEVD-dependent caspase-3 activity, streamlining apoptosis assays across immunology and neurodegeneration. Its robust workflow, sensitive readouts, and versatile application make it an essential tool for dissecting cell death pathways in complex disease models.

• DMH-1 (ALK2 Inhibitor): Precision Modulation of BMP Signalin

  2026-05-12

  Explore how DMH1, a potent ALK2 inhibitor, enables advanced control of BMP signaling for optimizing organoid stem cell differentiation and non-small cell lung cancer research. This in-depth analysis highlights practical assay insights and novel strategies not found in existing content.

• Fluconazole: Precision Ergosterol Biosynthesis Inhibitor (B2

  2026-05-12

  Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450 enzyme 14α-demethylase, disrupting ergosterol biosynthesis and cell membrane integrity. It is central to antifungal susceptibility testing and drug resistance research in Candida albicans models. APExBIO's B2094 formulation provides reproducible performance for in vitro and in vivo experiments.

• BMS-345541: Precision IKK-1/IKK-2 Inhibition in NF-κB Resear

  2026-05-11

  BMS-345541 is a potent and selective IKK-1/IKK-2 inhibitor, widely used for dissecting NF-κB signaling in inflammation and cancer research. Its efficacy in suppressing cytokine production and inducing apoptosis is supported by robust in vitro and in vivo evidence. APExBIO offers validated BMS-345541 (free base, B4655) for reproducible experimental workflows.

390 records 7/26 page Previous Next First page 上5页 678910 下5页 Last page